3 terminated, 1 active not recruiting, 1 completed, 1 not yet recruiting. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Waldenstrom's Macroglobulinemia Recurrent: new trials by email Literature Review of Waldenstrom's Macroglobulinemia Recurrent trials Research Report on Waldenstrom's Macroglobulinemia Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia Sonrotoclax, Zanubrutinib - Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent | Phase 2 | Active not recruiting | BeOne Medicines | 114 | 2023-10-23 | 2026-10-20 |
| Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL MB-106 - Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent | Phase 1 / Phase 2 | Terminated | Mustang Bio | 20 | 2022-05-24 | 2024-07-22 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse | Terminated | Mustang Bio | 3 | 2021-09-29 | 2024-07-22 | |
| Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia Ibrutinib, Daratumumab - Waldenstrom Macroglobulinemia, Waldenstrom's Disease | Phase 2 | Terminated | Weill Medical College of Cornell University | 1 | 2020-07-30 | 2023-10-23 |
| A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia ICP-022 - Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory | Phase 2 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 47 | 2019-08-10 | 2024-04-18 |
Recurrence (3) · Waldenstrom Macroglobulinemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Hypergammaglobulinemia (1) · Leukemia, Hairy Cell (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Disease Attributes (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3)
CLR1404 (1) · Dexamethasone (1) · Rituximab (1) · daratumumab (1) · ibrutinib (1) · zanubrutinib (1)
Mustang Bio (2) · BeOne Medicines (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Cellectar Biosciences, Inc. (1) · Weill Medical College of Cornell University (1)
United States (4) · China (2) · Australia (1) · Canada (1) · France (1) · Greece (1) · Italy (1) · Spain (1) · United Kingdom (1)
Bruce Dezube, M.D. (1) · John N. Allan, M.D. (1) · Mazyar Shadman, MD (1)
2023 (1), R44CA265616 (1)